New drug aims to keep kidney cancer in check without harsh treatment

NCT ID NCT07023432

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether the drug belzutifan can control metastatic clear cell renal cell carcinoma in people who are currently just being watched (active surveillance). Researchers will compare belzutifan to continued observation in 78 adults with slow-growing disease who have not had prior systemic treatment. The study also tracks side effects to see if belzutifan is safe enough to use as a first-line option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Belzutifan
What this could lead to: If it works, this could offer a way to delay or avoid more aggressive treatment for people with slow-growing metastatic kidney cancer.
What could go wrong: This is a small, early-phase trial, so results may not apply broadly. Belzutifan can cause side effects like anemia or low oxygen, and it may not control the cancer better than simply watching it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACTIVE SURVEILLANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACTIVE SURVEILLANCE CLEAR CELL RENAL CELL CARCINOMA

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.